To investigate the impact of liver function deterioration and survival rate during combined treatment of hepatocellular carcinoma patients
Sep 03, 2024
Professor Jeon Hong-jae's team at Cha Medical University Bundang Cha Hospital (Director Yoon Sang-wook) Cancer Center published the results of a study on the effect of liver function deterioration during the combination treatment of atezolizumab and bevacizumab on survival rates in patients with hepatocellular carcinoma. This study is the first in the world to systematically analyze the frequency and clinical importance of liver function decline during hepatocellular carcinoma treatment, and is evaluated as a study to inform the importance of liver function management in the treatment of immune cancer. The findings were published in the latest issue of the prestigious international journal Heptology (IF=12.9)' in the field of tumors.
Professor Jeon Hong-jae participated as a co-senior author in the study, which was jointly conducted by 25 medical institutions from three continents of Europe, the United States, and Asia. Professor Jeon Hong-jae was the only Asian researcher to participate in the study involving the University of Pittsburgh, the University of Chicago, and the University of Imperial College London.
The research team analyzed 571 patients who received combined treatment with atetzolizumab and bevacizumab after diagnosis of unresectable hepatocellular carcinoma (HCC) at 25 tertiary medical institutions in Europe, the United States, and Asia from January 2019 to June 2023. Bundang Cha Hospital, the only one in Korea to participate in the study, contributed to the study with 172 patients, the largest number in the world.
The research team confirmed that liver function decline occurs in 16.5% of patients who received the combination treatment of atezolizumab and bevacizumab. The risk of death of patients with decreased liver function was 19.0 times, which was higher than the risk of death of patients with worsened liver cancer during treatment by 9.9 times. Most patients with decreased liver function could not continue follow-up treatment, and only 13.8% of patients could receive second-line chemotherapy. On the other hand, 61.1% of the 51.3% patients whose tumors progressed without liver function decline were able to receive secondary systemic chemotherapy and showed a higher survival rate. In particular, it has been confirmed that this deterioration of liver function is more common in patients with liver cancer with high albumin-bilirubin (ALBI) grade or non-viral causes (alcohol, metabolic).
Professor Hong-jae Jeon (blood oncology) who is the head of the study confirmed that the deterioration of liver function as well as tumor progression is a key factor in determining the prognosis of liver cancer patients in determining the prognosis of hepatocellular carcinoma patients"By taking an integrated approach to liver function management and liver cancer treatment, we could significantly improve the survival rate of patients with liver cancer."
This study was conducted with the support of the Ministry of Science and ICT and the Korea Research Foundation's basic research project (medium-sized research).
Professor Jeon Hong-jae participated as a co-senior author in the study, which was jointly conducted by 25 medical institutions from three continents of Europe, the United States, and Asia. Professor Jeon Hong-jae was the only Asian researcher to participate in the study involving the University of Pittsburgh, the University of Chicago, and the University of Imperial College London.
The research team analyzed 571 patients who received combined treatment with atetzolizumab and bevacizumab after diagnosis of unresectable hepatocellular carcinoma (HCC) at 25 tertiary medical institutions in Europe, the United States, and Asia from January 2019 to June 2023. Bundang Cha Hospital, the only one in Korea to participate in the study, contributed to the study with 172 patients, the largest number in the world.
The research team confirmed that liver function decline occurs in 16.5% of patients who received the combination treatment of atezolizumab and bevacizumab. The risk of death of patients with decreased liver function was 19.0 times, which was higher than the risk of death of patients with worsened liver cancer during treatment by 9.9 times. Most patients with decreased liver function could not continue follow-up treatment, and only 13.8% of patients could receive second-line chemotherapy. On the other hand, 61.1% of the 51.3% patients whose tumors progressed without liver function decline were able to receive secondary systemic chemotherapy and showed a higher survival rate. In particular, it has been confirmed that this deterioration of liver function is more common in patients with liver cancer with high albumin-bilirubin (ALBI) grade or non-viral causes (alcohol, metabolic).
Professor Hong-jae Jeon (blood oncology) who is the head of the study confirmed that the deterioration of liver function as well as tumor progression is a key factor in determining the prognosis of liver cancer patients in determining the prognosis of hepatocellular carcinoma patients"By taking an integrated approach to liver function management and liver cancer treatment, we could significantly improve the survival rate of patients with liver cancer."
This study was conducted with the support of the Ministry of Science and ICT and the Korea Research Foundation's basic research project (medium-sized research).
|
bellho@sportschosun.com
